Home » Stocks » EGRX

Eagle Pharmaceuticals, Inc. (EGRX)

Stock Price: $47.70 USD -0.38 (-0.79%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 621.54M
Revenue (ttm) 186.14M
Net Income (ttm) 4.94M
Shares Out 13.53M
EPS (ttm) 0.35
PE Ratio 136.68
Forward PE 16.45
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $47.70
Previous Close $48.08
Change ($) -0.38
Change (%) -0.79%
Day's Open 47.62
Day's Range 47.00 - 48.86
Day's Volume 95,107
52-Week Range 34.37 - 58.31

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the ...

Business Wire - 2 weeks ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chie...

Business Wire - 2 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company's pre-recorded presentation at the Piper Sandler 3...

Seeking Alpha - 2 months ago

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 303.45% and 7.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

Business Wire - 2 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30,...

Business Wire - 2 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced four additions to its clinical, formulations and commercialization ...

Business Wire - 2 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial resu...

Business Wire - 4 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its Board of Directors has approved a $25 million accelerated ...

Business Wire - 4 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner, SymBio Pharmaceuticals Limited (“SymBio...

Business Wire - 4 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

Business Wire - 5 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

Seeking Alpha - 5 months ago

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 307.14% and 11.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 5 months ago

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were flat in pre-market trading after the company reported Q2 results.

Business Wire - 5 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

Business Wire - 5 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc.

Business Wire - 6 months ago

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has establi...

Seeking Alpha - 8 months ago

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 8 months ago

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected at $55.02 after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 8 months ago

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors Business Daily - 9 months ago

Eagle Pharmaceuticals stock popped Thursday after the pharmaceutical company said its hyperthermia drug, Ryanodex, showed promise as a potential coronavirus treatment in a laboratory test. Th...

Seeking Alpha - 10 months ago

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 37.14% and 8.45%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for t...

Zacks Investment Research - 10 months ago

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead fo...

Zacks Investment Research - 1 year ago

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 16.67% and 10.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the ...

Zacks Investment Research - 1 year ago

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 77.19% and 12.43%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the...

Zacks Investment Research - 1 year ago

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About EGRX

Eagle Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to trea... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 12, 2014
CEO
Scott Tarriff
Employees
108
Stock Exchange
NASDAQ
Ticker Symbol
EGRX
Full Company Profile

Financial Performance

In 2019, EGRX's revenue was $195.89 million, a decrease of -8.17% compared to the previous year's $213.31 million. Earnings were $14.31 million, a decrease of -55.14%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for EGRX stock is "Buy." The 12-month stock price forecast is 50.00, which is an increase of 4.82% from the latest price.

Price Target
$50.00
(4.82% upside)
Analyst Consensus: Buy